BioMedNewsBreaks — MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Announces Receipt of Regulatory Approval Powdery Mildew Bio-Fungicide in Canada

MustGrow Biologics (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, has received regulatory approval from Canada’s Pest Management Regulatory Agency (“PMRA”) for use of a powdery mildew bio-fungicide product; the approval covers use of the powdery mildew bio-fungicide suppression treatment on cannabis and hemp products. MustGrow announced more than a year ago that it had completed a definitive licensing agreement to obtain the exclusive treatment from a leading multinational biological and microbial company. The bio-fungicide product, which is not mustard derived, like MustGrow’s other products, is designed to treat powdery mildew, which is a widespread fungal disease that infects many plants, including cannabis and hemp. The regulatory approval allows MustGrow to sell the product under its trademark CannaPM(TM) as a foliar spray. The active ingredient in the powdery mildew bio-fungicide suppression treatment is Streptomyces, a biological fungicide/bactericide that suppresses a broad range of soil and foliar ornamental diseases. While MustGrow can now sell the product in Canada and has the exclusive option to expand internationally, the company’s main focus remains on its signature mustard-derived biopesticide and bioherbicide technologies to control diseases, pests, and weeds.

To view the full press release, visit https://ibn.fm/pFtER

About MustGrow Biologics Corp.

MustGrow is a publicly traded, agriculture biotech company focused on providing natural, science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a U.S. EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s Pest Management Regulatory Agency (“PMRA”) as a biopesticide for high-value crops, including fruits and vegetables. MustGrow has now concentrated a liquid format, TerraMG, that with regulatory approval could be applied through standard drip or spray equipment, improving functionality and performance features. In addition, this mustard-derived technology could have other applications in several different industries from pre-plant soil treatment to post harvest disease control and food preservation. For more information about the company, please visit www.MustGrow.ca. 

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF 

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork